Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age 18 to 75~* BMI greater than or equal to 25~* HbA1c greater than or equal to 7.5% and less than or equal to 10.5%~* Type 2 Diabetes Mellitus and on stable dose of oral metformin~* Agree to conduct home-based (fasted) blood glucose testing as directed~Exclusion Criteria:~* Clinically significant abnormalities in medical history or physical exam~* Show evidence of uncorrected hypothyroidism or hyperthyroidism hormone results~* History of renal transplantation or renal dialysis~* History of liver disease~* History of greater than 3 episodes of severe hypoglycemia within 6 months of screening~* Use of oral anti-diabetic medication other than metformin within 3 months of screening~* History of diabetic ketoacidosis~* Any other significant illness or condition that may interfere with the patient participating or completing the study~* Inability or unwillingness to comply with protocol or study procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ISIS-GCGRRx Dose Level 1 (Type: EXPERIMENTAL): ISIS-GCGRRx Dose Level 1
- ISIS-GCGRRx Dose Level 2 (Type: EXPERIMENTAL): ISIS-GCGRRx Dose Level 2
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).